Market Overview

Benzinga's Top #PreMarket Losers

Related ONTY
Oncothyreon And Celldex Therapeutics Announce Initiation Of Combination Immunotherapy Clinical Trial Of ONT-10 and Varlilumab
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside
Related RDEN
Benzinga's M&A Chatter for Wednesday August 27, 2014
Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend
Elizabeth Arden Weighs Strategic Options (Fox Business)

Oncothyreon (NASDAQ: ONTY) fell 15.47% to $2.35 in pre-market trading. Form 8-K from Oncothyreon showed that EMR 63325-009 did not meet endpoint.

Elizabeth Arden (NASDAQ: RDEN) shares slipped 15.45% to $16.58 in pre-market trading after the company reported a fiscal fourth-quarter loss. Elizabeth Arden reported that funds affiliated with Rhone Capital have agreed to buy $50 million in preferred shares and receive warrants for 2.5 million shares.

El Pollo Loco Holdings (NASDAQ: LOCO) shares declined 5.57% to $31.35 in pre-market trading. Morgan Stanley initiated coverage on El Pollo Loco with a Underweight rating and a $22.00 price target.

Target (NYSE: TGT) dropped 3.93% to $56.25 in pre-market trading. Target is expected to report its quarterly earnings on August 20, 2014.

Posted-In: PreMarket LosersNews Movers & Shakers Pre-Market Outlook Markets

 

Related Articles (ONTY + LOCO)

Around the Web, We're Loving...

Get Benzinga's Newsletters